Zika vaccine: early data demonstrate safety, immunogenicity

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Preliminary data show that a purified formalin-inactivated Zika virus (ZIKV) vaccine (ZPIV) has a good tolerability profile, and provides sufficient immunogenicity to offer clinical protection against ZIKV.
  • Initial data support larger, more advanced trials to further establish cl...